Observational studyBMC infectious diseases2026
Changes in myeloid-derived suppressor cells and cytokine expression during mother-to-child transmission prevention in HBeAg-positive pregnant women with chronic hepatitis B.
Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this study was to investigate the changes of Myeloid-derived suppressor cells (MDSCs) and cytokines expression during mother-to-child blockade in chronic HBV infected patients.
methodThis was a single-center, prospective, observational study. From August 2020 to January 2021, 30 pregnant women with chronic hepatitis B (HBV DNA ≥ 5 log10 IU/mL) were enrolled, and their alanine aminotransferase was within the normal range. The period of mother-to-child blockade was divided into T0 (no antiviral treatment), T1 (antiviral treatment for 4 weeks) and T2 (antiviral treatment for 8 weeks). A total of 10mL of peripheral blood was obtained at that three different time points. Flow cytometry was utilized to assess the proportion of MDSCs within the peripheral blood mononuclear cells. Additionally, plasma samples were preserved for the analysis of inflammatory cytokine levels.
resultsThirty were initiated on antiviral therapy during 24-28 weeks of gestation and 19 were monitored for up to 8 weeks after antiviral therapy. The average HBV DNA titer was 8.03 log10 IU/mL at the beginning of antiviral therapy, and decreased to 3.53log10 IU/mL at 8 weeks after antiviral. After antiviral treatment, the percentage of MDSCs significantly decreased from 16.24% (range 2.26-29.12%) at baseline to 9.53% (range 3.89-17.30%) at week 4 and 2.20% (range 0.45-3.95%) at week 8 (repeated-measures ANOVA, P < 0.01). There was no statistically significant correlation between the percentage of MDSCs and the serum HBsAg and HBeAg levels before and after mother-to-children blockade. There was no statistically significant correlation between the percentage of MDSCs (and its subsets) and HBV DNA quantification during follow-up. IL-10 level was positively correlated with the percentage of MDSCs. IFN-γ level was negatively correlated with the percentage of MDSCs (P < 0.0001). There was no statistically significant correlation between IL-6 and, GM-CSF and the percentage of MDSCs.
conclusionsMDSCs tended to decrease during mother-to-child blockade during pregnancy in HBV chronically infected patients, and monocytic MDSCs was predominant. Inflammatory cytokines IL-6 and GM-CSF were not major contributors to MDSCs levels during pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.